<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="newer antiviral drugs/vaccines under investigation. Keywords Angiotensin Angiotensin converting enzyme" exact="Chloroquine" post="Corona virus COVID-19 Cytokine storm RNA-dependent RNA polymerase Spike"/>
 <result pre="water by the kidney, and also attenuate inflammation through the" exact="nitric oxide" post="production (Fig.Â 4) [36]. On the contrary, ACE converts"/>
 <result pre="to exert anti-inflammatory and anti-fibrotic actions, stimulate the release of" exact="nitric oxide" post="and reduce blood pressure. SARS-CoV-2 binds to ACE2 to"/>
 <result pre="of smokers and patients with COPD express higher ACE2 receptor." exact="Nicotine" post="binds and enhances nicotinic acetylcholine receptors (nAChR), specifically the"/>
 <result pre="COPD express higher ACE2 receptor. Nicotine binds and enhances nicotinic" exact="acetylcholine" post="receptors (nAChR), specifically the Î±7subtype (Î±7-nAChR) in lungs and"/>
 <result pre="growing interest in the use of anti-malaria and anti-amebiasis drugs" exact="chloroquine" post="(CQ, N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) and hydroxychloroquine (HCQ), as potential treatments for"/>
 <result pre="use of anti-malaria and anti-amebiasis drugs chloroquine (CQ, N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) and" exact="hydroxychloroquine" post="(HCQ), as potential treatments for COVID-19. Chloroquine inhibits quinone"/>
 <result pre="(CQ, N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) and hydroxychloroquine (HCQ), as potential treatments for COVID-19." exact="Chloroquine" post="inhibits quinone reductase 2, which is involved in the"/>
 <result pre="the â€˜cytokine stormâ€™ through controlling the T lymphocyte activation [85]." exact="Azithromycin" post="together with HCQ was reported considerably more efficient for"/>
 <result pre="considered in different clinical trials [87]. Remdesivir, an analogue of" exact="adenosine" post="with broad-spectrum antiviral agent has shown a high capacity"/>
 <result pre="[89]. Recently, the mixture of three drugs, lopinavir, oseltamivir and" exact="ritonavir" post="has been proposed to mitigate the virulence to a"/>
 <result pre="of homocysteine-dependent trans-sulfuration pathway in COVID-19 infection. Hence, Vitamin B6," exact="folic acid," post="and Vitamin B12 should also be included in the"/>
 <result pre="pathway in COVID-19 infection. Hence, Vitamin B6, folic acid, and" exact="Vitamin B12" post="should also be included in the treatment regimen for"/>
 <result pre="molecular modeling studies reveal a new mechanism of action of" exact="chloroquine" post="and hydroxychloroquine against SARS-CoV-2 infectionInt J Antimicrob Agents202055510596032251731 35.QiuYZhaoYBWangQLiJYZhouZJLiaoCHet"/>
 <result pre="studies reveal a new mechanism of action of chloroquine and" exact="hydroxychloroquine" post="against SARS-CoV-2 infectionInt J Antimicrob Agents202055510596032251731 35.QiuYZhaoYBWangQLiJYZhouZJLiaoCHet al.Predicting the"/>
 <result pre="responses in retort to SARS-CoV-2 in an ageing population, consider" exact="N-acetylcysteine" post="as early therapeutic intervention. Version 2Toxicol Rep2020776877132632359 41.XiongYLiuYCaoLWangDGuoMJiangAet al.Transcriptomic"/>
 <result pre="the road not takenEur J Clin Invest202010e1333910.1111/eci.13339 51.HasanagicSSerdarevicFPotential role of" exact="memantine" post="in the prevention and treatment of COVID-19: its antagonism"/>
 <result pre="the prevention and treatment of COVID-19: its antagonism of nicotinic" exact="acetylcholine" post="receptors (nAChR) and beyondEur Respir J202018200161010.1183/13993003.01610-2020 52.WangBLiRLuZHuangYDoes comorbidity increase"/>
 <result pre="for tetracyclines in the treatment of COVID-19Pharmacotherapy202040548748832267566 74.CalyLDruceJDCattonMGJansDAWagstaffKMThe FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir Res202017810478732251768 75.WanYShangJSunSTaiWChenJGengQet"/>
 <result pre="studiesJ Biomol Struct Dyn20201111210.1080/07391102.2020.1776157 82.OrtegaJTSerranoMLJastrzebskaBClass A G protein-coupled receptor antagonist" exact="famotidine" post="as a therapeutic alternative against SARS-CoV2: an in silico"/>
 <result pre="in silico analysisBiomolecules2020106954 83.DevauxCARolainJMColsonPRaoultDNew insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int J Antimicrob"/>
 <result pre="vitroCell Discov202061632194981 85.ZhouDDaiSMTongQCOVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progressionJ Antimicrob Chemother20207571667167032196083 86.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine"/>
 <result pre="in preventing infection and progressionJ Antimicrob Chemother20207571667167032196083 86.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19J Biomol Struct Dyn2020161610.1080/07391102.2020.1752802"/>
</results>
